CytomX Therapeutics (CTMX) Upgraded to Buy at BidaskClub
BidaskClub upgraded shares of CytomX Therapeutics (NASDAQ:CTMX) from a hold rating to a buy rating in a report issued on Friday morning.
A number of other research analysts have also commented on the stock. Cantor Fitzgerald started coverage on shares of CytomX Therapeutics in a research report on Monday, October 23rd. They set an overweight rating and a $35.00 price target for the company. Bank of America boosted their price target on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a buy rating in a research report on Wednesday, October 4th. Zacks Investment Research lowered shares of CytomX Therapeutics from a buy rating to a hold rating in a research report on Friday, November 10th. ValuEngine lowered shares of CytomX Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Finally, Nomura upped their target price on shares of CytomX Therapeutics to $44.00 and gave the stock a buy rating in a research report on Wednesday, October 4th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $31.88.
CytomX Therapeutics (NASDAQ CTMX) traded down $0.09 on Friday, hitting $21.57. 1,321,403 shares of the stock were exchanged, compared to its average volume of 374,506. CytomX Therapeutics has a 12-month low of $10.40 and a 12-month high of $24.67.
A number of institutional investors have recently bought and sold shares of CTMX. Numeric Investors LLC bought a new stake in CytomX Therapeutics in the second quarter worth $9,730,000. State Street Corp lifted its stake in CytomX Therapeutics by 58.8% in the second quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock worth $6,914,000 after purchasing an additional 165,342 shares during the last quarter. OxFORD Asset Management LLP lifted its stake in CytomX Therapeutics by 425.6% in the third quarter. OxFORD Asset Management LLP now owns 166,079 shares of the biotechnology company’s stock worth $3,001,000 after purchasing an additional 134,484 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in CytomX Therapeutics by 1,063.5% in the second quarter. Goldman Sachs Group Inc. now owns 127,776 shares of the biotechnology company’s stock worth $1,980,000 after purchasing an additional 116,794 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in CytomX Therapeutics by 185.3% in the third quarter. American Century Companies Inc. now owns 169,799 shares of the biotechnology company’s stock worth $3,085,000 after purchasing an additional 110,283 shares during the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “CytomX Therapeutics (CTMX) Upgraded to Buy at BidaskClub” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/16/cytomx-therapeutics-ctmx-upgraded-to-buy-at-bidaskclub.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.